EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Concentration–QTc Relationship from a Single Ascending Dose Study of ANAVEX3‐71, a Novel Sigma‐1 Receptor and Allosteric M1 Muscarinic Receptor Agonist in Development for the Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer's Disease

Emmanuel O Fadiran, Edward Hammond, James Tran, Hongqi Xue, Janell Chen, Walter E Kaufmann, Christopher U Missling, Borje Darpo

Clinical Pharmacology in Drug Development · 2023

DOI: 10.1002/cpdd.1303 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2023. Verfasst von Emmanuel O Fadiran und 7 weiteren Autor:innen. Beteiligte Einrichtung: Anavex Life Sciences Corp., NY, USA. Hauptthemen laut MEDLINE: Receptors, sigma, Receptor, Muscarinic M1, Muscarinic Agonists. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This is the cardiodynamic evaluation of a single ascending dose study in healthy participants with the primary objective of assessing the effect of ANAVEX3‐71, formerly AF710B, on ECG parameters. Twelve‐lead ECGs were obtained at 3 time points within 1 hour prior to dosing to establish a baseline and then serially postdose. Concentration–QTc analysis of plasma concentrations of ANAVEX3‐71 and metabolite M8 was conducted. ANAVEX3‐71 at the studied doses did not have a clinically relevant effect on heart rate or on the PR and QRS intervals. ANAVEX3‐71 alone was retained in the primary model due to small fit differences between models which included the metabolite M8. The estimated population slope of the concentration–QTcF relationship was small and slightly negative: −0.017 ms per µg/L, with a small treatment effect‐specific intercept of −0.49 ms. An effect on the placebo‐corrected, change‐from‐baseline QTc exceeding 10 ms can be excluded within the full observed ranges of plasma concentrations of ANAVEX3‐71 and M8 up to ∼996 and ∼58 µg/L, respectively. The results from this cardiodynamic evaluation demonstrated that ANAVEX3‐71 at single ascending doses of 5‐200 mg had no clinically relevant effects on any of the studied ECG parameters.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, sigmaReceptor, Muscarinic M1Muscarinic AgonistsHumansMaleElectrocardiographyFemaleSigma-1 ReceptorAdultHeart RateAlzheimer DiseaseDose-Response Relationship, DrugSchizophreniaYoung AdultDouble-Blind MethodMiddle AgedHealthy Volunteers

Stichwörter der Autor:innen

ANAVEX3-71QTcFcardiodynamicsconcentration-QTcF relationshipdrug effectfirst-in-human

Substanzen

Sigma-1 ReceptorReceptors, sigmaReceptor, Muscarinic M1Muscarinic Agonists

Autor:innen und Institutionen

  • Anavex Life Sciences Corp., NY, USA.
  • ERT-Clario, Philadelphia, PA, USA.

Zitieren

APA

Fadiran, E. O., Hammond, E., Tran, J., Xue, H., Chen, J., Kaufmann, W. E., Missling, C. U., & Darpo, B. (2023). Concentration–QTc Relationship from a Single Ascending Dose Study of ANAVEX3‐71, a Novel Sigma‐1 Receptor and Allosteric M1 Muscarinic Receptor Agonist in Development for the Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer's Disease. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1303

Vancouver

Fadiran EO, Hammond E, Tran J, Xue H, Chen J, Kaufmann WE, et al. Concentration–QTc Relationship from a Single Ascending Dose Study of ANAVEX3‐71, a Novel Sigma‐1 Receptor and Allosteric M1 Muscarinic Receptor Agonist in Development for the Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer's Disease. Clinical Pharmacology in Drug Development. 2023. doi:10.1002/cpdd.1303

BibTeX
@article{Fadiran2023,
  author = {Fadiran, Emmanuel O and Hammond, Edward and Tran, James and Xue, Hongqi and Chen, Janell and Kaufmann, Walter E and Missling, Christopher U and Darpo, Borje},
  title = {Concentration–QTc Relationship from a Single Ascending Dose Study of ANAVEX3‐71, a Novel Sigma‐1 Receptor and Allosteric M1 Muscarinic Receptor Agonist in Development for the Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer's Disease},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2023},
  doi = {10.1002/cpdd.1303}
}
Kostenlos starten →